Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport versus Botox crossover study in adults with upper limb spasticity
2023-509196-16-00Phase 4Completed
- Sponsor
- Ipsen
- Start
- Mar 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, randomised, double-blind trial of botulinum toxin type A in upper extremity spasticity (2 arms), sponsored by Ipsen. Primary endpoint: Rate of treatment-emergent adverse events. Started Mar 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
upper extremity spasticity
Beyond the preview
Go deeper on 2023-509196-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509196-16-00.